Medium-chain triglyceride supplementation under a low-carbohydrate formula is a promising therapy for adult-onset type II citrullinemia.
Journal Information
Full Title: Mol Genet Metab Rep
Abbreviation: Mol Genet Metab Rep
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Genetics & Heredity
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflict of interest The authors had no potential conflicts of interest (COI) associated with this work."
"We thank Mr. Toshiyuki Yamauchi for advice on formula. This work was supported in part by a grant from the Ministry of Health, Labor and Welfare in Japan. The Ethics Committee of the Yamagata University School of Medicine approved a molecular analysis of SLC25A13 and our clinical trials of MCT therapy. Written informed consent for molecular analysis and involvement in the MCT clinical trials was obtained from all patients."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025